Ghost Tree Capital’s Blueprint Medicines BPMC Stock Holding History

Ghost Tree Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$12.9M	Buy	140,000 +100,000	+250%	+$9.93M	3.91%	5
2024 Q2	$4.31M	Sell	40,000 -32,761	-45%	-$3.28M	1.35%	29
2024 Q1	$6.9M	Buy	+72,761	New	+$6.24M	1.91%	16
2023 Q1	–	Sell	-20,000	Closed	-$876K	–	59
2022 Q4	$876K	Sell	20,000 -45,000	-69%	-$2.16M	0.37%	33
2022 Q3	$4.28M	Buy	+65,000	New	+$4.17M	1.2%	31
2020 Q1	–	Sell	-150,000	Closed	-$12M	–	52
2019 Q4	$12M	Sell	150,000 -175,000	-54%	-$13.1M	2.29%	15
2019 Q3	$23.9M	Sell	325,000 -50,000	-13%	-$4.32M	6.08%	3
2019 Q2	$35.4M	Buy	375,000 +135,000	+56%	+$11.1M	7.34%	4
2019 Q1	$19.2M	Buy	+240,000	New	+$17.7M	5.02%	4
2018 Q2	–	Sell	-120,000	Closed	-$11M	–	47
2018 Q1	$11M	Sell	120,000 -30,000	-20%	-$2.59M	2.23%	14
2017 Q4	$11.3M	Buy	+150,000	New	+$10.6M	2.65%	10
2017 Q3	–	Sell	-70,000	Closed	-$3.55M	–	66
2017 Q2	$3.55M	Sell	70,000 -30,000	-30%	-$1.27M	0.74%	52
2017 Q1	$4M	Buy	+100,000	New	+$3.58M	0.75%	46

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ghost Tree Capital's BPMC Position: Q3 2024 in Review

Ghost Tree Capital increased its Blueprint Medicines (BPMC) stake by 250% in Q3 2024, buying an estimated $9.93M and bringing the position to 140,000 shares worth $12.9M. The position accounts for 3.91% of the portfolio, ranked #5.

Ghost Tree Capital first reported a position in BPMC in Q1 2017 and has held it in 13 quarters since. The position peaked at $35.4M in Q2 2019. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

Ghost Tree Capital held 140,000 shares of Blueprint Medicines worth $12.9M as of Q3 2024.
Ghost Tree Capital bought 100,000 Blueprint Medicines shares in Q3 2024, an estimated $9.93M.
Blueprint Medicines made up 3.91% of Ghost Tree Capital's portfolio in Q3 2024, its #5 holding.
Ghost Tree Capital first reported a position in Blueprint Medicines in Q1 2017 and has held it in 13 quarters since.
Ghost Tree Capital's Blueprint Medicines position peaked at $35.4M in Q2 2019.
319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.